Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound - PubMed (original) (raw)
Comparative Study
Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound
Isabelle Vachier et al. J Allergy Clin Immunol. 2005 Jan.
Abstract
Background: Lipoxins and 15-epi-lipoxins are lipid mediators that modulate leukocyte trafficking and promote the inflammation resolution. They are produced by different enzymatic pathways. Patients with severe asthma present ongoing airway inflammation despite chronic long-term treatment including oral glucocorticoids.
Objectives: The aim of this study was to assess the presence of proinflammatory and anti-inflammatory mediators in the supernatants of induced sputum.
Methods: Induced sputum supernatants were collected from 10 normal subjects; 12 subjects with mild, 15 with moderate, and 24 with severe asthma; and 13 patients with chronic obstructive pulmonary disease. First, we validated the measurements of IL-8, leukotriene B 4 , lipoxin A 4 , and 15-epi-lipoxin A 4 in these samples. Then we measured these mediators by using immunoenzymatic methods.
Results: IL-8 levels were highly increased in patients with severe asthma ( P < .0001), and leukotriene B 4 levels were significantly increased in patients with severe asthma and patients with chronic obstructive pulmonary disease. Lipoxin A 4 was significantly increased in the supernatant obtained from patients with mild asthma ( P < .0001), whereas 15-epi-lipoxin A 4 levels were higher in patients with severe asthma ( P = .05). More interestingly, we found a positive correlation between the level of lipoxin A 4 and IL-8 in patients with mild asthma.
Conclusion: These results indicate that induced sputum is a suitable method to assess lipoxin and 15-epi-lipoxin measurements in bronchi. The mechanisms involved in the synthesis of these 2 eicosanoid mediators would be helpful to understand better the imbalance between proinflammatory and anti-inflammatory mediators occurring in severe asthma. Lipoxin production involves interaction between lipoxygenases, whereas 15-epi-lipoxin production might involve CytP450 activity.
Similar articles
- Lipoxins in asthma: potential therapeutic mediators on bronchial inflammation?
Bonnans C, Chanez P, Chavis C. Bonnans C, et al. Allergy. 2004 Oct;59(10):1027-41. doi: 10.1111/j.1398-9995.2004.00617.x. Allergy. 2004. PMID: 15355460 Review. - Effects of oral prednisone on sputum eosinophils and cytokines in patients with severe refractory asthma.
Dente FL, Bacci E, Bartoli ML, Cianchetti S, Costa F, Di Franco A, Malagrinò L, Vagaggini B, Paggiaro P. Dente FL, et al. Ann Allergy Asthma Immunol. 2010 Jun;104(6):464-70. doi: 10.1016/j.anai.2010.04.003. Ann Allergy Asthma Immunol. 2010. PMID: 20568377 Clinical Trial. - Lipoxins are potential endogenous antiinflammatory mediators in asthma.
Bonnans C, Vachier I, Chavis C, Godard P, Bousquet J, Chanez P. Bonnans C, et al. Am J Respir Crit Care Med. 2002 Jun 1;165(11):1531-5. doi: 10.1164/rccm.200201-053OC. Am J Respir Crit Care Med. 2002. PMID: 12045128 - Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution.
Serhan CN. Serhan CN. Prostaglandins Leukot Essent Fatty Acids. 2005 Sep-Oct;73(3-4):141-62. doi: 10.1016/j.plefa.2005.05.002. Prostaglandins Leukot Essent Fatty Acids. 2005. PMID: 16005201 Review. - Profiles of proinflammatory cytokines in sputum from different groups of severe asthmatic patients.
Dente FL, Carnevali S, Bartoli ML, Cianchetti S, Bacci E, Di Franco A, Vagaggini B, Paggiaro P. Dente FL, et al. Ann Allergy Asthma Immunol. 2006 Sep;97(3):312-20. doi: 10.1016/S1081-1206(10)60795-8. Ann Allergy Asthma Immunol. 2006. PMID: 17042136
Cited by
- Leukotriene B4 Receptors Are Necessary for the Stimulation of NLRP3 Inflammasome and IL-1β Synthesis in Neutrophil-Dominant Asthmatic Airway Inflammation.
Kwak DW, Park D, Kim JH. Kwak DW, et al. Biomedicines. 2021 May 11;9(5):535. doi: 10.3390/biomedicines9050535. Biomedicines. 2021. PMID: 34064821 Free PMC article. - Bronchoprotective mechanisms for specialized pro-resolving mediators in the resolution of lung inflammation.
Duvall MG, Bruggemann TR, Levy BD. Duvall MG, et al. Mol Aspects Med. 2017 Dec;58:44-56. doi: 10.1016/j.mam.2017.04.003. Epub 2017 May 17. Mol Aspects Med. 2017. PMID: 28455109 Free PMC article. Review. - Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study.
Follows RM, Snowise NG, Ho SY, Ambery CL, Smart K, McQuade BA. Follows RM, et al. Respir Res. 2013 May 17;14(1):54. doi: 10.1186/1465-9921-14-54. Respir Res. 2013. PMID: 23682661 Free PMC article. Clinical Trial. - Resolution of inflammation in asthma.
Levy BD, Vachier I, Serhan CN. Levy BD, et al. Clin Chest Med. 2012 Sep;33(3):559-70. doi: 10.1016/j.ccm.2012.06.006. Epub 2012 Jul 25. Clin Chest Med. 2012. PMID: 22929102 Free PMC article. Review. - Resolution of acute inflammation in the lung.
Levy BD, Serhan CN. Levy BD, et al. Annu Rev Physiol. 2014;76:467-92. doi: 10.1146/annurev-physiol-021113-170408. Epub 2013 Dec 2. Annu Rev Physiol. 2014. PMID: 24313723 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical